The initial focus will be on treatments for lysosomal storage disorders, rare haematology and ophthalmology conditions. Credit: Anton Darius on Unsplash.

Italian pharmaceutical company Chiesi Farmaceutici (Chiesi Group) has established a global division for the research and development of rare and ultra-rare diseases treatments.

The business unit will be in Boston, Massachusetts, US. Initially, the focus will be on lysosomal storage disorders, rare haematology and ophthalmology conditions.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Currently, the company markets medicines for alpha‑mannosidosis and nephropathic cystinosis, two types of lysosomal storage disorders, in some regions outside the US. Chiesi is also working to develop therapies for other rare diseases.

In 2018, the company obtained the commercialisation rights to pegunigalsidase alfa (PRX-102) in the US. PRX-102 is an investigational drug being developed in Phase III clinical trials to treat Fabry disease.

Chiesi Global Rare Diseases head Giacomo Chiesi said: “We are dedicated to making rapid progress in our research and development programmes and to being an active partner in opportunities to support patients and families.

“There are more than 7,000 rare diseases and for the vast majority there are no treatments available. We are very excited to put Chiesi’s decades of experience in drug development and dedication to patients to work to make a positive difference in the treatment of many rare diseases in the years ahead.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Chiesi and its partner Protalix BioTherapeutics also entered into an agreement with the US Food and Drug Administration (FDA) for initial paediatric study plan (iPSP) of PRX-102.

Protalix BioTherapeutics president and CEO Dror Bashan said: “Proceeding with the paediatric study plan for PRX-102 marks an important milestone in our goal of bringing an alternative to the Fabry patient community which is in need of better treatment options other than those currently available.”